C4 Therapeutics (CCCC) Return on Equity (2020 - 2026)

C4 Therapeutics' Return on Equity history runs 7 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Equity was 0.0% for Q1 2026 at C4 Therapeutics, up from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.01% in Q3 2025.
• Historically, Return on Equity has averaged 0.0% across 5 years, with a median of 0.0% in 2023.
• Biggest YoY gain for Return on Equity was 0 bps in 2022; the steepest drop was 0 bps in 2022.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then sank by 36 bps to 0.01% in 2023, then gained by 20 bps to 0.0% in 2024, then retreated by 11 bps to 0.01% in 2025, then increased by 17 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.